We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Sentinel Diagnostics

Sentinel Diagnostics develops and manufactures in-vitro diagnostic medical devices for routine analysis and specific ... read more Featured Products: More products

Download Mobile App

Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: The SENTiNAT 200 platform contains everything labs need to perform complete PCR analysis (Photo courtesy of Sentinel Diagnostics)
Image: The SENTiNAT 200 platform contains everything labs need to perform complete PCR analysis (Photo courtesy of Sentinel Diagnostics)

Sentinel Diagnostics (Milano, Italy) is presenting its newly-launched SENTiNAT 200 fully automated sample to result system, and STAT-NAT SN200 Real-Time PCR assays for the quantitative detection of 10 viruses at MEDICA 2022. The new SENTiNAT 200 and STAT-NAT SN200 kits represent the ideal solution for mid to large throughput laboratories engaged in the diagnosis of viral infections.

SENTiNAT 200 is a compact platform for DNA/RNA extraction, PCR set up and amplification that includes two integrated thermal cyclers and the FastFinder analysis software. The system combines throughput, automation and flexibility to better adapt to the various laboratory needs. It performs multi-parametric analysis of up to 15 viruses in the same run, processing from one up to 48 samples in four hours. The intuitive software that guides the operator through all the phases of the instrument set up, along with the barcode reader for samples and reagents help to reduce human error. The operator can access to the data available on the cloud anytime anywhere, to optimize reporting time while maintaining full control over the results.

SENTiNAT 200 is designed to work with STAT-NAT SN200 kits, based on the freeze-dried patented technology that allows long term stability at room temperature, making the assays more robust and simplifying reagent management in the laboratory. Also on display at the Sentinel booth at MEDICA 2022 is the recently launched SENTiFIT 800 high-throughput and fully automated solution for fecal immunochemical tests. SENTiFIT 800 represents the solution to help laboratories in the diagnosis of CRC as well as other digestive diseases.

“We developed the SENTiNAT 200 and STAT-NAT SN200 kits, all CE-marked, to offer a complete solution, that simplifies the routine activities of virology laboratories, including those dedicated to transplant patient,” said Marco Buonaguidi, Head of Sales and Marketing. “Today, we take a first step on a path that will see us committed to developing new parameters to satisfy the most challenging requests of our clients in molecular diagnostics.”

Related Links:
Sentinel Diagnostics 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.